PDF
ePub
Citation
Print
INTRODUCTION
Hemiplegic shoulder pain (HSP) is a very common complication after stroke [1]. Paralysis imposes a condition of immobility that may contribute to the development of glenohumeral joint stiffness which secondarily may cause pain [2]. Diagnosis of HSP typically is based on a combination of clinically signs and symptoms of shoulder pain. However the mechanisms of pain have not been clearly identified, and HSP is difficult to define. It is classified as adhesive capsulitis, shoulder subluxation, complex regional pain syndrome, and central pain according to its causes [3]. After stroke, the primary changes to the hemiplegic shoulder complex include poor positioning of the scapula and the humerus, and immobility. The association found between spasticity, limited range of motion (ROM) and shoulder pain highlights the relationship between the altered biomechanics of the shoulder joint and HSP. For this reason HSP can be defined as a chronic pain syndrome that is consequent to the changes in the musculoskeletal elements of the shoulder complex [45]. The clinical presentation of HSP mimics that of adhesive capsulitis [6]. Gamble stated that adhesive capsulitis was found significantly more often among hemiplegic patients than the normal population [7]. However, the exact etiology of HSP remains unknown and many factors may be involved. The most common problem is that it interrupts upper limb rehabilitation and daily activities [8].
There have been no specific approaches and management guidelines for HSP patients. Generally, non-surgical treatments of HSP have various options. These may include physical therapies such as positioning of the upper limb, wearing shoulder hemiplegic slings, taking oral pain relievers, applying a moist heating pad, and using of functional electrical stimulation and therapeutic ultrasound. These treatments must be aimed at returning the patients to their daily activities and improving the ROM of the shoulder.
Steroid injections are frequently used for their local anti-inflammatory effect. However, it is well-known that repeated intra-articular steroid (IAS) therapy interferes with cartilage metabolism and may lead to rapid destruction of the joint, resulting in joint arthropathy [9101112]. Nakazawa et al. [13] demonstrated in animal studies that steroid induces chondrocyte apoptosis and arthropathy.
There are many studies investigating the efficacy of hyaluronic acids for pain relief and their effect on the metabolism of articular cartilage, synovial tissue and fluid. Hyaluronic acid might have an anti-inflammatory effect in addition to a regeneration effect since it is a component of cartilage matrix such as glycosaminoglycan and proteoglycan [1415]. Although intra-articular hyaluronic acid (IAHA) injection has shown some promising results in the treatment of patients with adhesive capsulitis, its effect remains controversial.
A previous study in a non-stroke population showed that the effects of IAHA and steroid on adhesive capsulitis were similar [16]. However, there are no previous studies in stroke patients comparing the effects of IAHA versus steroid injection on HSP. The purpose of this study was to compare the efficacy of IAHA with IAS injection on post-stroke HSP.
MATERIALS AND METHODS
Study subjects
A single-blind, randomized, controlled clinical study comparing the effect of IAHA and IAS on pain and ROM was carried out with post-stroke patients with HSP. The study period was May 2012 to October 2013. The study subjects were patients who were hospitalized at the rehabilitation center of Pusan National University Yangsan Hospital or were presented to the clinic with HSP. The informed consent form was approved by the Institutional Review Board of Pusan National University Yangsan Hospital prior to the study.
The study subjects were 31 patients who developed post-stroke hemiplegia and HSP within the first 3 months after stroke had a limited passive ROM of a capsular pattern on physical examination and had a Wong-Baker Scale (WBS) score of at least 2. Subjects who had mild or no cognitive function impairments with Mini-Mental State Examination above 20 and could accurately reflect the degrees of pain that they experienced during the study were included.
Subjects were excluded if they had previous shoulder diseases such as rheumatoid arthritis or complex regional pain syndrome type 1 on the affected shoulder, a resistance greater than a Modified Ashworth Scale score of 3, previous history of trauma, previous steroid injection, pain or disability of the wrist joint, elbow joint, and metacarpophalangeal joints, or a communication disorder due to aphasia. If multiple combinations of drugs were used to alleviate patient's pain, those cases were also excluded from the study.
Physical examination and ultrasonography (US) were performed to evaluate HSP. One of the authors who is a board certified physiatrist (Lee) with 10 years of experience in ultrasonographic evaluation and musculoskeletal rehabilitation, conducted the manual muscle testing of the rotator cuff, and evaluated the degree of pain of the affected shoulder including the possibility of shoulder impingement syndrome using Neer, Hawkins, and Yocum tests. The study subjects underwent US by the same physiatrist to check for rotator cuff impingement syndrome and tendonitis, full thickness rotator cuff tear, calcification of the shoulder, and abnormality of subacromial bursa and biceps, and they were excluded if they had any abnormalities. In addition, patients who were recently taking anti-platelet or anticoagulant agents stopped these medications 5 days prior to the injection to prevent injection-induced hemorrhage.
Study methods
A total of 31 subjects randomized into two groups, underwent an US-guided intra-articular injection into the shoulder with the following medications:
With patients in a sitting position the injections were performed using an US-guided posterior approach at the exact injection site confirmed by expansion of the shoulder joint capsule. The patient was in a sitting position with the ipsilateral hand crossing the chest. The scapular spine was palpated, and the ultrasound probe was placed just caudal and parallel to the lateral end of the spine. A 22-gauge needle was inserted in-plane from the lateral aspect of the probe and directed between the edge of the labrum and the humeral head [17]. To limit the effects of oral pain relievers, single dose of NSAIDs was given to both groups. Patients in group A received three injections weekly, while patients in group B received a single injection in the 1st week. Moreover, the injection volume used in each group was equally 6 mL to prevent any effect of hydrostatic pressure expansion and to focus only on the pharmacological effects of the hyaluronic acid and steroids. All patients underwent 1 hour of physical therapy 5 times per week for 3 weeks during the hospitalization period. Physical therapy such as active and passive joint movement with transcutaneous electrical nerve stimulation therapy was performed, and the physical therapists were educated about the physical therapy program before the study began in order to standardize the therapeutic program.
The assessment of therapeutic effects was performed prior to the start of the study, and in the 1st, 4th, and 8th weeks. WBS scores were evaluated at night (night pain) and during the day (movement pain). WBS is a 6-item horizontal scale with 6 facial expressions for clinical pain assessment. The first face represents 'no pain' and the 6th face represents 'the worst possible pain'. Patients were asked to mark the face that expresses their level of pain. Face figures are scored between 0 and 10, the least score representing 'no pain' [18]. The passive shoulder ROM was evaluated using a goniometer in every direction except adduction and internal rotation in the supine position. The degrees of shoulder flexion and abduction were measured with the elbow in extension in supine position. The ROM of external rotation was evaluated with 90° of shoulder abduction and elbow flexion was evaluated with the arm in the side position. In order to measure the exact ROM, the joint should be positioned and the proximal segment stabilized, thereby isolating the articular movement being evaluated. The passive ROM was measured by the examiner moving each subject's arm until limited mechanically or by pain. The physiatrist who carried out the initial assessment and performed the intra-articular injection did not participate in follow-up assessments. Follow-assessments were conducted by clinical examiners with over 2 years of experience in the treatment of HSP patients.
The patients were randomized into two groups: group A received an IAHA injection followed by physical therapy, while group B received an IAS injection followed by physical therapy. Randomization was performed using the block randomization method prior to the clinical trial.
Statistical analysis
Sample size was calculated with statistical power analysis program G*Power ver. 3.1 (http://www.gpower.hhu.de/). For alpha of 0.05 (2-tailed test), 80% power, 2 groups, 35 subjects were required. A total of 40 subjects would be necessary to allow for 15% loss to follow-up.
In this study, subjects that provided baseline and at least 1 post-injection assessment constituted the intention-to-treat (ITT) analysis, whereas those who completed all follow-up assessment from baseline to the 8th week constituted the per protocol (PP) analysis. For the ITT analysis, outcome measurements were analyzed using the last observation carried forward (LOCF) method.
Variations in ROM and WBS after injection treatment of the two groups were compared using the Mann-Whitney U test. Statistical significance was analyzed using the Friedman test to assess the changes over time in each group. The Wilcoxon signed-rank test was performed as a post-hoc test in cases of a significant difference. Measurements were repeated three times with the mean values being used in analysis. Statistical significance was defined at p-values <0.016 using Bonferroni correction. The statistical program SPSS ver. 18.0 (SPSS Inc., Chicago, IL, USA) was used for the statistical analysis.
RESULTS
Patient demographics
A schematic of the study is shown in Fig. 1. A total of 62 subjects were recruited. Twenty-three of, these had shoulder pathology confirmed by US and physical examination such as full thickness rotator cuff tear, calcification of the shoulder, subacromial bursitis and were excluded. After the first follow-up assessment (1st week after the injection), 8 subjects were lost because of admission to other hospitals, poor general condition or they refused follow-up assessments (Fig. 1). No significant side effects were observed in either group over the 8-week follow-up period. The mean age of the study subjects in group A was 56.6±11.3 years, while that of those in group B was 60.8±13.7 years. In group A, 11 (52%) patients had cerebral hemorrhage, while 10 (48%) had cerebral infarction; in group B, 8 (44%) had cerebral hemorrhage and 10 (56%) had cerebral infarction. At baseline, there was no significant difference between the group A and group B in age, sex, stroke type, and duration of stroke (Table 1).
Change in the passive ROM of the shoulder
Intention-to-treatment analysis using the LOCH method
The 39 subjects who had follow-up assessments at least once were included in the ITT analysis. At baseline, the passive flexion of the shoulder was 112.1°±28.53° in group A and 122.2°±32.00° in group B while, the passive external rotation of the shoulder prior to injection treatment was 38.6°±24.65° in group A and 27.5o±23.02o in group B.
In the group A, passive ROM of the shoulder showed significant improvement of flexion (p=0.006 at 4th week, p=0.003 at 8th week) and external rotation (p=0.006 at 4th week, p=0.003 at 8th week) after 4th week post-injection. In the group B, passive ROM of flexion (p=0.014) and external rotation (p=0.004) showed significant improvement only at 8th week (Table 2). However, post-hoc testing showed no significant difference between the two groups over 8 weeks (p>0.05).
Per protocol analysis
The 31 subjects who completed 8 weeks follow-up assessments were included in the PP analysis. The passive flexion of the shoulder prior to injection treatment was 117.2°±27.20° in group A and 124.0°±34.08° in group B while, the passive external rotation of the shoulder prior to injection treatment was 32.8°±24.90° in group A and 27.3°±24.49° in group B.
In group A, passive ROM of the shoulder showed significant improvement of flexion (p=0.007 at 4th week, p=0.004 at 8th week), external rotation (p=0.007 at 4th week, p=0.010 at 8th week) after 4th week post-injection. In the group B, passive ROM of shoulder showed significant improvement of external rotation (p=0.010) only at the 8th week. The improvement in passive ROM of the shoulder was greater in the group A at 4th week than in the group B. There was statistically significant improvement at the 8th week in both groups (Fig. 2). However, post hoc testing showed no significant difference between the two groups after 8 weeks (p=0.299 in flexion, p=0.861 in external rotation at 8th week).
Change in shoulder pain and WBS scores
Intention-to-treatment analysis using the LOCH method
The WBS score for night pain prior to injection treatment was 3.8±2.74 in group A and 2.2±2.41 in group B, and movement pain was 5.9±1.64 in group A and 6.5±1.72 in group B.
In group A, both night pain (p=0.003 at 4th week, p=0.002 at 8th week) and movement pain (p=0.001 at 4th week, p=0.000 at 8th week) were significantly decreased. In the group B, only movement pain was significantly decreased from 1st week post-injection (p=0.001 at 1st week, p=0.000 at 4th and 8th weeks). However, there was no significant difference between two groups for either night pain or movement pain over the time.
Per protocol analysis
In the group A, both night pain (p=0.011 at 4th week, p=0.007 at 8th week) and movement pain (p=0.006 at 4th week, p=0.001 at 8th week) significantly decreased after 4th week post-injection. In the group B, only movement pain was significantly decreased 1 week after injection and thereafter (p=0.002 at 1th week, p=0.001 at 4th and 8th weeks). However, there was no significant difference between groups for either night pain (p=0.740 at 8th week) or movement pain (p=0.711 at 8th week) after 8 weeks (Fig. 3).
DISCUSSION
HSP usually develops after stroke, with 35% of cases of HSP developing within 2 weeks after stroke, and 72% of cases developing within 3 months after stroke [19]. HSP often causes difficulties, not only in activities of daily living but also in the effect of rehabilitation programs performed after stroke. It also negatively affects in functional recovery, and is associated with pain-induced depression and secondary complications of the shoulder [720].
HSP is clinically very similar to adhesive capsulitis. It is known that muscle contracture develops due to constant immobility in hemiplegic patients, thus is accompanied by adhesive capsulitis [21]. A recent study of 106 HSP patients reported, that 56.6% had adhesive capsulitis, 17.9% shoulder subluxation, 13.2% complex regional pain syndrome, and 12.6% central pain [3]. Previous studies also reported that the main cause of HSP is adhesive capsulitis [22]. Another study reported a significant correlation between pain, limited ROM in hemiplegic shoulder and adhesive capsulitis [20]. Unfortunately, adhesive capsulitis may be the last stage due to chronic inflammation, injury and immobility in untreated HSP patients [23]. The earlier adhesive capsulitis is diagnosed in HSP patients, the more likely it is that treatment can help prevent longterm pain and stiffness.
Minor synovitis including edema, vascular dilation, and monocyte precipitation has been found in some patients with adhesive capsulitis, and steroid injection treatment is the therapy used with the expectation of an antiinflammatory effect [24]. Because fibrosis in the joint capsule plays the most important role in the inflammatory reaction, anti-inflammatory treatment is necessary to stop the fibrosis and improve the symptoms. When the effects of steroid injection dose and frequency in IAS treatment on shoulder pain were compared to the effects of steroid injection in combination with physical therapy in previous studies, no study reported that steroid treatment only would have better effects than other treatments.
Among the non-surgical treatments applicable to most stroke patients with HSP, oral analgesics and nonsteroidal anti-inflammatory drugs are not fully effective, and the risk of developing adverse effects from long-term drug use is high, especially in the elderly [2526]. Also, the steroid used in IAS treatment in HSP patients has a usage limit because of the possibility of systemic and local adverse effects [6].
Hyaluronic acid is a long chain of polysaccharides composed of N-acetyl glucosamine and glucuronic acid. This forms the framework of proteoglycans and enables aggregation in the extracellular matrix; thus, it is an essential component in the structure and function of joint cartilage. The presence of hyaluronic acid in the joint cavity reduces the coefficient of friction and directly increases synovial fluid viscosity and elasticity. This provides a buffering effect for compressive and shearing forces and, has a role in protecting a joint. IAHA has been used in adhesive capsulitis due to its therapeutic effects such as reduced synovitis, influence on osmotic pressure, cartilage protective effect, prevention of intra-articular adhesions, and enhancement of the characteristics of synovial fluid [27].
According to the multicenter study performed by Blaine et al. [28], hyaluronic acid was relatively effective for the treatment of osteoarthritis that was not responsive to other non-surgical treatment. However, in the comparative study performed by Calis et al. [29], IAHA was not effective in patients with adhesive capsulitis compared to physical therapy or IAS. According to a recently conducted randomized controlled trial, IAHA had no additional effect on pain, ROM, and quality of life in patients with adhesive capsulitis who had already received physical therapy [30]. Another study showed that IAHA and IAS treatments gave significant improvement in passive ROM and a visual analog scale [16]. However, failure to accurately inject the joint cavity could not be excluded because the injection was performed in a blind manner in these previous studies. The accuracy of intra-articular injection in a blind manner is only 70% however, US guidance improves the accuracy of joint injection [31]. All of the injections in this study were performed using a posterior US-guided approach and injection accuracy was verified by checking the joint cavity expansion.
Many researchers have reported a positive effect of hydraulic distension in shoulder pain in non-stroke patients [32333435]. Thus, this study was designed to control any effect of hydraulic distension by injecting the same volume in all subjects, thus comparing only the pharmacological effects of hyaluronic acid and steroid.
In our study, shoulder pain and ROM improved significantly in both the IAHA and IAS groups. In the steroid group, it effectively controlled pain, especially during the early phase, which is probably due to the anti-inflammatory effect of the steroid. However, there was no great difference in the improvement of ROM or movement pain after 4 weeks of treatment in the IAHA or IAS group. For night pain, only the IAHA group had a statistically significant effect indicating that hyaluronic acid had a sufficient analgesic and anti-inflammatory effect compared to the steroid.
The significant of this study is that IAHA effectively controls HSP and improves ROM, and its efficacy does not differ from IAS at the 8th week of treatment. In other words, hyaluronic acid can be used when the steroid cannot be used due to concerns of diabetes and infection risk. Despite the treatment being administered to stroke patients in the acute and sub-acute phases of HSP, no adverse reactions of hyaluronic acid were observed.
One limitation of this study is that long-term clinical effects were not investigated due to the 8-week observational period. To overcome this limitation, a future study with long-term follow-up and observation after IAHA and IAS would be necessary. Second, the worsening of HSP is associated with the development and increase in spasticity after stroke. The early stage of this study was performed only in patients with minor spasticity of the upper extremities, so a study that compares the effect of treatment on spasticity as well as the effect of hyaluronic acid is needed. Third, although several confounding factors were controlled including medication and intensity of physical therapies, multiple factors might still have induced the pain of the patients including thalamic pain, insomnia and systemic diseases. The initial NSAIDs prescription for all subjects would also bring about the improvement of shoulder pain in HSP patients.
Nevertheless, our study could be meaningful as the first study to evaluate the efficacy of the hyaluronic acid injection compared to the steroid injection on poststroke HSP. Further study should be followed with more samples and controlling other confounding factors which could affect pain.
In conclusion, IAHA is less potent than IAS for reducing shoulder pain in stroke patients with HSP in the early period. However, there was no statistically significant difference after 4 weeks post-injection between the two groups. Based on the results of this study, IAHA could be an alternative treatment for managing HSP when the use of steroid is limited.
XML Download